QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ensysce-biosciences-ensc-stock-is-down-30-today-whats-going-on

Ensysce Biosciences shares are trading lower by 30% during Thursday's session. The company announced a $5 million registere...

 watching-ensysce-biosciences-zacks-small-cap-research-gives-stock-1725-price-valuation

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_08152024_ENSC_Sorensen.pdf

 ensysce-biosciences-q2-eps-022-beats-039-estimate-sales-18180k-miss-30000k-estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $...

 ensysce-biosciences-regains-nasdaq-compliance

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company d...

 ensysce-biosciences-renews-collaboration-with-quotient-sciences-to-undertake-the-study-pf614-mpar-102-to-examine-and-evaluate-the-full-commercial-dose-range-of-the-pf614-mpar-drug-product

New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPARSAN DIEGO, CA / ACCE...

 ensysce-biosciences-q1-2024-gaap-eps-055-beats-090-estimate-sales-305722k-miss-400000k-estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION